Two-Part Discussion About Developing and Deploying a COVID-19 Vaccine
"The critical issue here is that a vaccine is the way we're going to get out of this pandemic...The challenge is should those go to a few who are able to pay and get high coverage, leaving the rest of the countries with no vaccine? Or should we have a district distribution across the world?"—Seth F. Berkley, Chief Executive Officer, Gavi, the Vaccine Alliance
Have you read?
For the first session about the latest research and development updates, listen to Paul Stoffels, Vice-Chairman of the Executive Committee, Chief Scientific Officer, Johnson & Johnson; Magdalena Skipper, Editor-in-Chief, Nature; and Pascal Soriot, Chief Executive Officer, AstraZeneca, discuss how scientists are working hard to fast-track the development of a safe and effective vaccine that would typically take decades of work.
The second panel included Seth F. Berkley, Chief Executive Officer, Gavi, the Vaccine Alliance; Julie Gerberding, Executive Vice-President and Chief Patient Officer, MSD; Richard Hatchett, Chief Executive Officer, Coalition for Epidemic Preparedness and Innovations (CEPI); Sai Prasad, President, DCVMN. With efforts to develop a COVID-19 vaccine racing ahead, leaders face the unprecedented challenge of manufacturing and distributing a vaccine worldwide. The discussion focused on how stakeholders can work together to ensure a safe, effective and globally accessible vaccine.